New chemo combo aims to control liver cancer without surgery
NCT ID NCT03727633
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tested a treatment for liver cancer (hepatocellular carcinoma) in people with mild-to-moderate cirrhosis. The treatment involved injecting a chemotherapy drug (idarubicin) mixed with a fatty substance (lipiodol) directly into the liver artery. The main goal was to see if the cancer could be controlled (shrink or stay stable) for at least 4 months. The study included 44 adults whose cancer could not be removed by surgery or other local treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU d'Angers
Angers, 49933, France
-
CHU de Dijon
Dijon, 21079, France
-
CHU de Montpellier
Montpellier, 34295, France
-
CHU de Nice
Nice, 06202, France
Conditions
Explore the condition pages connected to this study.